2-Chlorodeoxyadenosine in the Treatment of Hairy Cell Leukemia and Chronic Lymphocytic Leukemia

References

• Piro L. D., Carrera C. J., Carson D. A., Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2–chlorodeoxyadenosine. N. Engl. J. Med. 1990; 322: 1117–1121
   PubMed Web of Science ®Google Scholar
• Piro L. D., Saven A., Ellison D., Thurston D., Carson D. A., Beutler E. Prolonged complete remissions following 2–chlorodeoxyadenosine (2–CdA) in hairy cell leukemia (HCL). Proc. Am. Soc. Clin. Oncol. 1992; 11: 846, Abstract
   Google Scholar
• Juliusson G., Liliemark J. Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2–chloro-2′-deoxyadenosine (CdA): Relation to opportunistic infections. Blood 1992; 79: 888–894
   PubMed Web of Science ®Google Scholar
• Estey E. M., Kurzrock R., Kantarjian H. M., O'Brien S., McCredie K., Beran M., Koller C., Keating M., Hirsch-Ginsberg C., Huy Y. O., Stass S., Freireich E. Treatment of hairy cell leukemia with 2–chlorodeoxyadenosine (2–CdA). Blood 1992; 79: 882–887
   PubMed Web of Science ®Google Scholar
• Tallman M. S., Hakimian D., Variakojis D., Koslow D., Sisney G. A., Rademaker A. W., Rose E., Kaul K. A single cycle of 2–chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 9: 2203–2209
   Google Scholar
• Lauria F., Benfenati D., Zinzani P. L., Raspadori D., Rondelli D., Tura S. 2–Chlorodeoxyadenosine in the treatment of hairy cell leukemia patients relapsed after α-interferon. Blood 1991; 78(Suppl. 1)34a, Abstract
   Google Scholar
• Piro L. D., Carrera C. J., Beutler E., Carson D. A. 2–chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 1988; 72(3)1069–1073
   PubMed Web of Science ®Google Scholar
• Saven A., Camera C. J., Carson D. A., Beutler E., Piro L. D. 2–Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leukemia and Lymphoma 1991; 5(Suppl.)133–138
   PubMed Web of Science ®Google Scholar
• Juliusson G., Elmhorn-Rosenborg A., Liliemark I. Response to 2–chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N. Engl. J. Med. 1992; 327: 1056–1061
   PubMed Web of Science ®Google Scholar
• Juliusson G., Liliemark J. High complete remission rate from 2–chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count. J. Clin. Oncol. 1993; 11: 679–689
   PubMed Web of Science ®Google Scholar
• Kay A. C., Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2–Chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol. 1992; 10: 371–377
   PubMed Web of Science ®Google Scholar
• Saven A., Carrera C. J., Carson D. A., Beutler E., Piro L. D. 2–Chlorodeoxyadenosine: An active agent in the treatment of cutaneous T-cell lymphoma. Blood 1992; 80: 587–592
   PubMed Web of Science ®Google Scholar
• Kuzel T., Samuelson E., Roenigk H., Trop E., Rosen S. Phase II trial of 2–chlorodeoxyadenosine (2–CdA) for the treatment of mycosis fungoides or the Sezary syndrome (MF-SS). Proc. Am. Soc. Clin. Oncol. 1992; 11: 1089, Abstract
   Google Scholar
• Giblett E. R., Anderson J. E., Cohen F., Pollara B., Meuwissen H. J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 1972; 2: 1067–1069
   PubMed Web of Science ®Google Scholar
• Cohen A., Hirshhorn R., Horowitz S. D., Rubinstein A., Polmar S. H., Hong R., Martin D. W., Jr. Deox-yadenosine triphosphate as a potentially toxic metabolite in adenosine deaminase deficiency. Proc. Natl. Acad. Sci. USA 1978; 75: 472–476
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Kaye J., Ullman B., Martin D. W., Jr., Robins R. K., et al. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs towards malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl. Acad. Sci. USA 1980; 77: 6865–6869
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Taetle R., Yu A. Specific toxicity of 2–chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737–743
   PubMed Web of Science ®Google Scholar
• Kawasaki H., Camera C. J., Piro L. D., Saven A., Kipps T. J., Carson D. A. Relationship of deoxycytidine kinase and cytoplasmic 5′-nucleotidase to the chemothera-peutic efficacy of 2–chlorodeoxyadenosine. Blood 1993; 81: 597–601
   PubMed Web of Science ®Google Scholar
• Seto S., Camera C. J., Kubota M., Wasson D. B., Carson D. A. Mechanism of deoxyadenosine and 2–chlorodeoxyadenosine toxicity to nondividing human lymphocytes. J. Clin. Invest. 1985; 75: 377–383
   PubMed Web of Science ®Google Scholar
• Seto S., Carrera C. J., Wasson D. B., Carson D. A. Inhibition of DNA repair by deoxyadenosine in resting human lymphocytes. J. Immunol. 1986; 136: 2839–2843
   PubMed Web of Science ®Google Scholar
• Camera C. J., Piro L. D., Miller W. E., Carson D. A., Beutler E. Remission induction in hairy cell leukemia by treatment with 2–chlorodeoxyadenosine: Role of DNA strand breaks and NAD depletion. Clin. Res. 1987; 35: 597A, Abstract
   Google Scholar
• Carrera C. J., Terai C., Piro L., Saven A., Beutler E., Carson D. 2–chlorodeoxyadenosine chemotherapy triggers programmed cell death in normal and malignant lymphocytes. J. Purine Pyrimidine Res. 1991; 2(Suppl. l)15–38
   Google Scholar
• Bouroncle B. A., Wiseman B. K., Doan C. A. Leukemic reticuloendotheliosis. Blood 1958; 13: 609–630
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Catovsky D., Golde D. W. Hairy cell leukemia: A clinical review of 71 cases. Ann. Intern. Med. 1978; 89: 677–683
   PubMed Web of Science ®Google Scholar
• Mintz U., Golomb H. M. Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res. 1979; 39: 2366–2370
   PubMed Web of Science ®Google Scholar
• Jansen J., Hermans J. Splenectomy in hairy cell leukemia: A retrospective multicenter analysis. Cancer 1981; 47: 2066–2076
   PubMed Web of Science ®Google Scholar
• Golomb H. M., Ratain M. J. Recent advances in the treatment of hairy-cell leukemia. N. Engl. J. Med. 1987; 316: 870–872
   PubMed Web of Science ®Google Scholar
• Quesada J. R., Reuben J., Manning J. T., Hersh E. M., Gutterman J. U. Alpha-interferon for induction of remission in hairy cell leukemia. N. Engl. J. Med. 1984; 310: 15–18
   PubMed Web of Science ®Google Scholar
• Spiers A. S. D., Moore D., Cassileth P. A., Harrington D. P., Cummings F. J., Neiman R. S., Bennett J. M., O'Connell M. J. Remissions in hairy-cell leukemia with pentostatin (2′-deoxycoformycin). N. Engl. J. Med. 1987; 316: 825–871
   PubMed Web of Science ®Google Scholar
• Saven A., Piro L. D. Treatment of hairy cell leukemia. Blood 1992; 79: 1111–1120
   PubMed Web of Science ®Google Scholar
• Cassileth P. A., Cheuvant B., Spiers A. S. D., Hanington D. P., Cummings F. J., Neiman R. S., Bennett J. M., O'Connell M. J. Pentostatin induces durable remissions in hairy cell leukemia. J. Clin. Oncol. 1991; 9: 243–246
   PubMed Web of Science ®Google Scholar
• Carrtra C. J., Piro L. D., Saven A., Cox K., Beutler E., Carson D. A., Kipps T. J. Restoration of lymphocyte subsets following 2–chlorodeoxyadenosine remission induction in hairy cell leukemia. Blood 1990; 76(Suppl. 1)260a, Abstract
   Google Scholar
• Hoffman M., Rai K., Sawitsky A., Janson D. 2–chlorodeoxyadenosine (2–CdA) in hairy cell leukemia. Blood 1991; 78(Suppl. 1)454a, Abstract
   Google Scholar
• Saven A., Piro L. D. Complete remissions in hairy cell leukemia with 2–chlorodeoxyadenosine after failure with 2′-deoxycoformycin. Ann. Intern. Med. 1993; 119: 278–283
   PubMed Web of Science ®Google Scholar
• Liliemark J., Albertioni F., Hassan M., Petterson B., Juliusson G. On the bioavailability of oral and subcutaneous 2–chloro-2′-deoxyadenosine in humans: Alternative routes of administration. J. Clin. Oncol. 1992; 10: 1514–1518
   PubMed Web of Science ®Google Scholar
• Liliemark J., Petterson B., Juliusson G. The relationship between plasma 2–chloro-2′-deoxyadenosine (CdA) and cellular CdA nucleotides (CdAn) after intermittent and continuous i.v. infusion in patients with chronic lymphocytic leukemia. Blood 1991; 78(Suppl.)33a, (Abstract)
   Google Scholar
• Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J., Foon K. A. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am. J. Hematol. 1988; 29: 152–163
   PubMed Web of Science ®Google Scholar
• Saven A., Lemon R. H., Piro L. D. 2–Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia (letter). N. Engl. J. Med. 1993; 328: 812–813
   PubMed Web of Science ®Google Scholar
• Urba W. J., Baseler M. W., Kopp W. C., Steis R. G., Clark J. W., Smith J. W., II, Coggin D. L., Longo D. L. Deoxycoformycin-induced immunosuppression in patients with hairy cell leukemia. Blood 1989; 73: 38–46
   PubMed Web of Science ®Google Scholar
• Carson D. A., Wasson D. B., Esparza L. M., Carrera C. J., Kipps T. J., Cottam H. B. Oral anti-lympho-cytic activity and induction of apoptosis by 2–chloro-2′arabino-fluoro-2′-deoxyadenosine (CAFdA). Proc. Natl. Acad. Sci. USA 1992; 89: 2910–2974
   Web of Science ®Google Scholar